Skip to main content
. 2018 Aug 20;128(9):4057–4073. doi: 10.1172/JCI96400

Figure 5. Stabilin-2 deficiency increases the half-life of human VWF-FVIII.

Figure 5

(A) Plasma levels of VWF:Ag were measured in age-matched normal C57BL/6 mice compared with stabilin-2–deficient (STAB2-KO) C57BL/6 mice (n = 26–38 animals per condition by t test). (B and C) Influence of stabilin-2 deficiency on the half-life of infused human rVWF (n = 12 animals per condition) (B) and human pdVWF (FVIII-bound 1:1) (n = 16 animals per condition) (C). (D) The combined influence of macrophage depletion using clodronate liposomes and stabilin-2 deficiency was assessed using human pdVWF (FVIII-free) (n = 8 animals per condition). (E) The combined influence of cyclophosphamide-induced LSEC cytotoxicity and stabilin-2 deficiency was assessed using human pdVWF (FVIII-free) (n = 8–16 animals per condition). (F) The influence of stabilin-2 deficiency on the half-life of infused human pdFVIII (+VWF) (n = 16 animals per condition) was measured in VWF-KO compared with VWF/STAB2 DKO mice. See statistical summary of half-life studies in Table 1.